About EirGenix
About EirGenix
Vision and Mission
Milestones
Facilities and Capacities
Xizhi Facility
Zhubei Facility
Management Team
LEE-CHENG LIU
Klaus Martin
CHIH-JUNG CHANG
PORTIA LIN
HSIU-CHUAN YANG
SHANG-CHUNG JU
AE-NING LIN
HARK CHEN
Ywan-Feng Li
Videos
360-Degree Virtual Tour
News
EirGenix Activities
News
Events
Services
Cell Line Development
Process Development
Analytical & Quality Control
cGMP Manufacturing - Mammalian System
cGMP Manufacturing - Microbial System
ADC & Bioconjugates
Products & Pipeline
Commercial / Market-Available Products
(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
Pipeline — Biologic Therapeutic Candidates
Supporting Products & Platforms
HRV3C Protease
CRM197
Investor
Financials
Monthly Revenue
2025
2024
2023
2022
2021
2020
2019
2018
Financial Reports
2024
2023
2022
2021
2020
2019
2018
Corporate Governance
Corporate Governance
Board of Directors
Internal Audit
Shareholder Services
Shareholders' Meeting
Investor Conference
Dividend Distribution
Market Observation Post System
Investor Relations & Media Contact
Stock Transfer Agent
ESG
ESG Overview
Recruiting
|
EN
|
繁中
0
Inquiry
EN
繁中
Contact us
0
Inquiry
About EirGenix
About EirGenix
Vision and Mission
Milestones
Facilities and Capacities
Xizhi Facility
Zhubei Facility
Management Team
LEE-CHENG LIU
Klaus Martin
CHIH-JUNG CHANG
PORTIA LIN
HSIU-CHUAN YANG
SHANG-CHUNG JU
AE-NING LIN
HARK CHEN
Ywan-Feng Li
Videos
360-Degree Virtual Tour
News
EirGenix Activities
News
Events
Services
Cell Line Development
Process Development
Analytical & Quality Control
cGMP Manufacturing - Mammalian System
cGMP Manufacturing - Microbial System
ADC & Bioconjugates
Products & Pipeline
Commercial / Market-Available Products
(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar
Pipeline — Biologic Therapeutic Candidates
Supporting Products & Platforms
HRV3C Protease
CRM197
Investor
Financials
Monthly Revenue
2025
2024
2023
2022
2021
2020
2019
2018
Financial Reports
2024
2023
2022
2021
2020
2019
2018
Corporate Governance
Corporate Governance
Board of Directors
Internal Audit
Shareholder Services
Shareholders' Meeting
Investor Conference
Dividend Distribution
Market Observation Post System
Investor Relations & Media Contact
Stock Transfer Agent
ESG
ESG Overview
Recruiting
|
EN
|
繁中
Search
×
Submit
×
Home
News
News
News
News
EIRGENIX'S PHASE III CLINICAL TRIAL OF EG12014 HAS ENROLLED FIRST PATIENT
2018/10/30
More
CANCER THERAPEUTIC DRUG EG12014 IS APPROVED FOR PHASE III CLINICAL TRIAL
2018/05/22
More
EIRGENIX IS AWARD TOP 145 OF THE TECHNOLOGY FAST 500 COMPANIES IN ASIA PACIFIC (APAC)
2018/05/09
More
EIRGENIX RECEIVED "ASIA'S BEST CMO"
2018/01/31
More
EIRGENIX RECEIVED THE ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM JAPAN
2017/11/08
More
EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" BEAM-RAISING CEREMONY
2017/10/19
More
CANCER THERAPEUTIC DRUG EG12014 PASSED THE DOUBLE-BLINDED PHASE I CLINICAL TRIAL
2017/05/02
More
EIRGENIX RECEIVED "GRAND WINNER OF BEST BIOPROCESS EXCELLENCE IN TAIWAN"
2017/02/16
More
EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" GROUNDBREAKING CEREMONY
2016/12/30
More
2015 TAIWAN BIO-MEDICAL AND NEW AGRICULTURAL INDUSTRY DRAFT COMPETITION AWARDS CEREMONY
2015/09/24
More
EIRGENIX AND FORMOSA LABORATORIES COLLABORATE TO ESTABLISH A PLATFORM FOR ADC CMC INTEGRATION SERVIC
2014/06/23
More
EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
2013/12/06
More
‹
1
2
3
